234 results on '"Radhakrishna, Ganesh"'
Search Results
2. Impact of motion management strategies on abdominal organ at risk delineation for magnetic resonance-guided radiotherapy
3. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial
4. The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study
5. Conformal 3D computed tomography planned endoluminal brachytherapy for the local control of esophageal cancer
6. The multi-societal European consensus on the terminology, diagnosis and management of patients with synchronous colorectal cancer and liver metastases: an E-AHPBA consensus in partnership with ESSO, ESCP, ESGAR, and CIRSE
7. Low muscle mass measured at T12 is a prognostic biomarker in unresectable oesophageal cancers receiving chemoradiotherapy
8. Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial
9. Use of a non-endoscopic immunocytological device (Cytosponge™) for post chemoradiotherapy surveillance in patients with oesophageal cancer in the UK (CYTOFLOC): A multicentre feasibility study
10. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma
11. Radiology Training for Clinical Oncology Trainees
12. Patient and Public Involvement Refines the Design of ProtOeus: A Proposed Phase II Trial of Proton Beam Therapy in Oesophageal Cancer
13. Evaluation of a collapsed-cone convolution algorithm for esophagus and surface mold 192Ir brachytherapy treatment planning
14. PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development.
15. Proton versus photon therapy for esophageal cancer – A trimodality strategy (PROTECT) NCT050555648
16. Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position
17. PACT-UK (PAncreatic Cancer reporting Template–UK): a cross-specialty multi-institutional consensus panel development of a standardised radiological reporting proforma for pancreatic cancer
18. Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century
19. 178 Impact of Dose in Oligometastatic Liver SABR: A UK Single-Centre Experience
20. P021 / #650 - PROTON BEAM THERAPY FACILITATES DEFINITIVE CHEMORADIOTHERAPY FOR OESOPHAGEAL CANCER PATIENTS OTHERWISE UNSUITABLE FOR CURATIVE INTENT TREATMENT
21. Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment?
22. Optimising treatment pathways for borderline and locally advanced pancreatic cancer: an adaptive personalised approach
23. 2204: Motion management strategy and interobserver variation in abdominal OAR delineation using MRI
24. 2197: Evaluation of accumulated OAR dose DIR methods for MR-guided pancreas SABR
25. 1264: Functional adaptation using MR for liver sparing SABR
26. 990: Isotoxic five-fraction radiotherapy to treat oligometastasis adjacent to Gastrointestinal tract.
27. 389: Dose escalation in oesophageal cancer: comparing inter-reviewer variation within the UK SCOPE2 trial
28. NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma
29. Reply to Comment on “The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic”
30. Adaptive MR-linac guided stereotactic ablative radiotherapy for pancreatic adenocarcinoma: a single-institution experience
31. Stereotactic radiotherapy for HCC: real-world outcomes and multidisciplinary working
32. Time to level up treatment for less survivable cancers
33. Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century
34. Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer
35. The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study
36. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)
37. A Multi-Centre Randomised Phase II Trial of Early Pet-Ct Directed Switch to Carboplatin and Paclitaxel Based Definitive Chemoradiotherapy in Patients with Oesophageal Cancer Who Have a Poor Early Response to Induction Cisplatin and Capecitabine
38. HPB P51 The impact of the SARS-CoV-2 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study
39. The case of need for image-guided radiotherapy training for clinical oncology specialist trainees: Impact assessment post-COVID
40. A single-institution study of hypofractionated precision abdominal IMRT: A safe alternative when SABR is not deliverable
41. Outcomes following implementation of a specialist protocol for radiation-induced oesophageal strictures following radical radiotherapy
42. Postgraduate oncological training: Developing an adaptive oncology-focused teaching programme for central doctors rotating to the Christie NHS Foundation Trust
43. Evaluation of the impact of teaching on delineation variation during a virtual SABR contouring workshop
44. The Glasgow Prognostic Score at the Time of Palliative Esophageal Stent Insertion is a Predictive Factor of 30-Day Mortality and Overall Survival
45. Normo- or Hypo-Fractionated Photon or Proton Radiotherapy in the Management of Locally Advanced Unresectable Pancreatic Cancer: A Systematic Review.
46. Treatment planning comparison in the PROTECT-trial randomising proton versus photon beam therapy in oesophageal cancer: Results from eight European centres
47. Stereotactic ablative radiotherapy to the lower limb for metastatic melanoma
48. Challenges facing cancer care and guidance on prioritising its safe delivery: lessons from the COVID-19 pandemic
49. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial
50. Radiotherapy respiratory motion management in hepatobiliary and pancreatic malignancies: a systematic review of patient factors influencing effectiveness of motion reduction with abdominal compression
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.